Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial

• Published in: Journal of surgical oncology Vol. 115; no. 8; pp. 917 - 923
• Main Authors: Bear, Harry D., Wan, Wen, Robidoux, André, Rubin, Peter, Limentani, Steven, White, Richard L., Granfortuna, James, Hopkins, Judith O., Oldham, Dwight, Rodriguez, Angel, Sing, Amy P.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 15.06.2017
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Aromatase Inhibitors - therapeutic use; Biopsy; Biopsy, Large-Core Needle; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Cancer surgery; chemotherapy; Chemotherapy, Adjuvant; Clinical Decision-Making; Female; gene expression; Gene Expression Profiling - methods; hormonal therapy; Humans; Mastectomy, Segmental; Middle Aged; neoadjuvant; Neoadjuvant Therapy; Pilot Projects; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Tumors; hormonal therapy; breast cancer; neoadjuvant; chemotherapy; gene expression

Objective We hypothesized that the Oncotype Dx® 21‐gene Recurrence Score (RS) could guide neoadjuvant systemic therapy (NST) to facilitate breast conserving surgery (BCS) for hormone receptor positive (HR+) breast cancers. Methods This study enrolled patients with HR+, HER2‐negative, invasive breast...